Literature DB >> 19364044

[Osteitis as a complication of BCG vaccination].

Akira Koyama1, Ichiro Toida, Shizuko Nakata.   

Abstract

OBJECTIVES: To investigate the incidence and increasing tendency of osteitis after BCG vaccination and, in addition, its clinical features, diagnostic methods and results of treatment.
SUBJECTS: 22 cases of Japanese children who received BCG vaccination between 1998 and 2007 and developed osteitis, and were reported in medical journals or meetings. RESULTS AND DISCUSSION: Incidence was very low, 0.2 per 100,000 vaccinations, and an increasing tendency was not seen after 2005, when the vaccination in Japan was limited to below 6 months after birth. However, it might be necessary to follow for much longer period. About 73% of cases of osteitis were seen from 9 to 18 months after receiving the vaccination. The bones of the extremities were commonly affected. Radiography usually showed the defect and cavity formation of the affected bone and often abscess around the lesion. Definitive diagnosis was made by the detection of BCG from the pus or biopsied materials. Recently, multiplex PCR method have been utilized and proved to be a rapid and reliable diagnostic method. Tuberculin reaction was positive, but QFT was negative in all tested cases; QFT will be available for the differential diagnosis of BCG and tuberculous infection. Only 2 patients had multiple lesions, and they had partial interferon-gamma receptor 1 deficiency. Immunodeficiency might have some relationship to the development of osteitis after BCG vaccination. The treatment using INH and RFP was very effective and the outcome was favorable; most of the patients were cured after 6 to 12 months chemotherapy without any complications. However, there is the possibility of defects occurring in the bone and restriction of the articular movement when the diagnosis and treatment are delayed.
CONCLUSION: BCG osteitis, although rare, should be considered as a possible complication of the BCG vaccination, and early diagnosis and treatment of this complication is necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364044

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  6 in total

1.  Bacille Calmette-Guérin Vaccine-Induced Tuberculous Hip Osteomyelitis in an Infant: Case report.

Authors:  Mohammed S Al-Azri; Jazel Manarang; Yaqoub Al-Mufargi
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

2.  Mycobacterium bovis BCG-associated osteomyelitis/osteitis, Taiwan.

Authors:  Nan-Chang Chiu; Meng-Chin Lin; Wen-Li Lin; Shin-Yi Wang; Hsin Chi; Li-Min Huang; Ren-Bin Tang; Yhu-Chering Huang; Ching-Chuan Liu; Fu-Yuan Huang; Tzou-Yien Lin
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

3.  Mycobacterial Arthritis at 19 Months After a Bacille Calmette-Guérin Vaccination.

Authors:  Chien-Yu Lin; Ye-Ming Lee; Jeng-Jung Chen
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

4.  The Necessity of a Nationwide Surveillance System of Serious BCG Adverse Reactions.

Authors:  Hye-Kyung Cho
Journal:  J Korean Med Sci       Date:  2019-01-02       Impact factor: 5.354

5.  Mycobacterium bovis Osteitis Following Immunization with Bacille Calmette-Guérin (BCG) in Korea.

Authors:  Youn Young Choi; Mi Seon Han; Hoan Jong Lee; Ki Wook Yun; Chang Ho Shin; Won Joon Yoo; Tae-Joon Cho; Jung-Eun Cheon; Kyoung Un Park; Eun Hwa Choi
Journal:  J Korean Med Sci       Date:  2018-12-26       Impact factor: 2.153

6.  BCG Moreau Vaccine Safety Profile and NK Cells-Double Protection Against Disseminated BCG Infection in Retrospective Study of BCG Vaccination in 52 Polish Children with Severe Combined Immunodeficiency.

Authors:  Ewa Bernatowska; Małgorzta Skomska-Pawliszak; Beata Wolska-Kuśnierz; Małgorzata Pac; Edyta Heropolitanska-Pliszka; Barbara Pietrucha; Katarzyna Bernat-Sitarz; Nel Dąbrowska-Leonik; Nadia Bohynikova; Barbara Piątosa; Anna Lutyńska; Ewa Augustynowicz; Ewa Augustynowicz-Kopeć; Maria Korzeniewska-Koseła; Maria Krasińska; Katarzyna Krzysztopa-Grzybowska; Anna Wieteska-Klimczak; Janusz Książyk; Teresa Jackowska; Mirjam van den Burg; Jacques J M van Dongen; Jean-Laurent Casanova; Capucine Picard; Bożena Mikołuć
Journal:  J Clin Immunol       Date:  2019-11-20       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.